Financial Performance and Tigris Trial Insights
TORONTO — Spectral Medical Inc. (“Spectral”) (TSX: EDT), a leader in theranostics aiming to combat sepsis and septic shock, has shared its financial performance for the recently completed fiscal year and outlined critical advancements in its Tigris trial.
Throughout the year, Spectral made substantial strides, particularly emphasizing the Tigris trial, a Phase III clinical evaluation of PMX, its treatment for endotoxic septic shock. As of now, the company has successfully recruited 154 patients, moving closer to the crucial goal of full enrollment.
Strategies to Enhance Enrollment in the Tigris Trial
As the Company accelerates its efforts, it has onboarded additional sites since late 2023, aiming to bolster patient enrollment. The proactive onboarding strategy aims to propel the Tigris trial towards its target of 150 evaluable patients, which is a crucial step towards seeking FDA approval.
Dr. John Kellum, Spectral’s Chief Medical Officer, noted, "We are entering the critical final phase of our Tigris trial. The ongoing patient enrollments signal a positive trajectory, and we remain optimistic about achieving full enrollment shortly. Our work in advancing PMX is crucial for reducing the severe mortality rates associated with sepsis, which continues to be a significant global health concern."
Corporate Highlights and Collaborations
Spectral continues to collaborate closely with Vantive US Healthcare LLC, its commercialization partner, on various projects. A key accomplishment recently was the completion of the PrisMax sub-study, which has set the foundation for PMX's future commercialization efforts.
Vantive has plans to submit a 510(k) application to gain clearance for the PrisMax System, which holds great promise as the primary device for PMX treatments in intensive care units across the U.S.
Recent Achievements in Tigris Enrollment
- Total of 154 patients randomized as of now.
- Meanwhile, 59 patients were enrolled in 2024, markedly higher than the 31 recruited the previous year.
- In early 2025, 14 patients have already enrolled, showcasing a robust start.
Management estimates that only two to four more patient enrollments are needed to complete the trial fully. Meeting these targets is not just a number; achieving the required statistical data in both the PMX and standard-of-care arms is vital for safety analysis critical for regulatory review.
Financial Review and Updates
Financially, Spectral reported a 43% revenue increase, with 2024 generating $2,286,000 compared to $1,598,000 in 2023. Their quarterly revenue also saw a significant rise, with figures reaching $645,000.
Operating expenses for the year concluded at $17,681,000 compared to $17,105,000 from the previous fiscal year. A core element of these expenses stemmed from ongoing clinical and regulatory program costs amounting to $3,973,000, a slight decrease due to reduced activity in clinical site initialization.
Future Outlook for Spectral Medical
Despite a reported loss from continuing operations of $15,395,000 for the fiscal year, the company ended 2024 with a cash balance of $2,988,000. This reflects a steady financial position for continuing its essential clinical and commercialization activities.
Chris Seto, CEO of Spectral, emphasized the necessity of advancing PMX as they inch closer to trial completion: "Finalizing the Tigris trial represents a significant milestone for our team. The next few weeks are vital for Spectral as we look toward regulatory evaluations and potential market introduction."
About Spectral Medical
Spectral Medical is at the forefront of developing advanced treatments for septic shock. Their product, Toraymyxin™ (PMX), is an innovative therapeutic hemoperfusion device that removes endotoxins from the bloodstream. Currently, PMX is approved for use in Japan and Europe and has seen successful application over 360,000 times globally.
The FDA granted PMX Breakthrough Device Designation, illustrating its importance in the treatment landscape for endotoxin-induced septic shock. Approximately 330,000 patients are diagnosed with septic shock annually in North America alone, highlighting the critical need for effective therapies.
Frequently Asked Questions
What is the main focus of Spectral Medical?
Spectral Medical is focused on developing therapeutic options for sepsis and septic shock, with PMX being a notable product.
How is the Tigris trial progressing?
The Tigris trial currently has 154 patients enrolled, approaching its target of 150 evaluable patients to submit data to the FDA.
What recent financial results did Spectral report?
Spectral reported a 43% increase in revenue year-over-year, with fiscal 2024 totals reaching $2,286,000.
Who is Spectral's commercialization partner?
Spectral collaborates with Vantive US Healthcare LLC in advancing the commercialization of PMX.
What is PMX, and how is it used?
PMX is a hemoperfusion device designed to remove endotoxins from the blood, offering a potential treatment for patients suffering from septic shock.
